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The oxidative modiﬁcation of low-density lipoprotein (LDL) in the intima of arteries contributes to the
initiation and progression of atherosclerotic lesions. We have previously reported that oxidized LDL
(oxLDL) interacts with an endogenous plasma protein, b2-glycoprotein I (b2GPI), to form complexes
and that the interaction is mediated by oxLDL speciﬁc ligands. We have also demonstrated the presence
of oxLDL/b2GPI complexes in the blood stream of patients with systemic inﬂammatory and
autoimmune diseases. These ﬁndings implicate that oxLDL/b2GPI complexes are possible atherogenic
autoantigens. Autoantibodies to oxLDL/b2GPI complexes have been associated with arterial
thrombosis. Further, circulating IgG immune complexes containing oxLDL and b2GPI were also
detected in patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome
(APS). Although many unanswered questions remain about the exact pathogenic mechanism(s)
involved, oxLDL/b2GPI complexes may be described as metabolic products relevant in atherogenesis
and as signiﬁcant participants in autoimmune-mediated atherosclerosis.
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INTRODUCTION
Atherosclerosis is a major health concern of worldwide
importance. The experimental evidence has established a
causal relationship between atherosclerosis and lipo-
protein metabolism. More recently, inﬂammatory and
immunologic mechanisms have been linked to the
initiation and progression of atherosclerotic lesions.
In particular, the oxidation of low-density lipoprotein
(LDL) was identiﬁed as an early pro-atherogenic event
that promotes the formation of macrophage-derived foam
cells (Steinbrecher et al., 1984; Steinberg et al., 1989;
Steinberg, 1997; Heinecke, 1997).
The premature occurrence of atherosclerotic lesions
associated with signiﬁcant cardiovascular morbidity and
mortality in patients with systemic autoimmune diseases,
suggested a contributing role of autoimmunity in the
development of atherosclerosis. The antiphospholipid
syndrome (APS), frequently diagnosed in the contextof an
autoimmune disease, is characterized by arterial and
venous thromboembolic complications associated with
high serum levels of antiphospholipid antibodies
(Harris et al., 1983; Hughes et al., 1986). APS is a pro-
thrombotic state likely precipitated by the appearance of
anticardiolipin (aCL), lupus anticoagulants (LA) and/or
other antiphospholipid antibodies. It is now commonly
accepted that the plasma protein b2-glycoprotein I
(b2GPI) represents a major antigenic target for antiphos-
pholipid antibodies in patients with APS (McNeil
et al., 1990; Galli et al., 1990; Matsuura et al., 1990,
1992, 1994).
Oxidized LDL (oxLDL) is the principal lipoprotein that
accumulates within cells of atherosclerotic lesions and it
co-localizes with b2GPI (George et al., 1999). These
ﬁndings further suggested the participation of anti-
phospholipid antibodies in atherogenesis. In 1993, it was
ﬁrst reported that aCL antibodies from patients with
systemic lupus erythematosus (SLE) cross-reacted with
malondialdehyde (MDA)-modiﬁed LDL (Vaarala et al.,
1993). In contrast, it was shown that anti-b2GPI
antibodies but not aCL were associated with arterial
thrombosis (Tinahones et al., 1998; Romero et al., 1998).
We have recently demonstrated that oxLDL binds to
endogenous b2GPI and that these complexes
(oxLDL/b2GPI) can be found circulating in the blood
stream of patients with various chronic diseases, such as
SLE, APS, chronic renal disease, diabetes mellitus.
Further, IgG immune complexes formed by oxLDL,
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in SLE and APS patients (Kobayashi et al., 2003).
Our recent in vitro experiments showed that
oxLDL/b2GPI complexes were internalized by macro-
phages via an anti-b2GPI antibody-mediated phago-
cytosis (Hasunuma et al., 1997; Kobayashi et al., 2001;
Liu et al., 2002; Kobayashi et al., 2003). Thus, circulating
oxLDL/b2GPI and/or their IgG immune complexes are
most possibly atherogenic. In contrast, recent reports
indicated that natural antibodies (mainly of the IgM class)
derived from hyperlipidemic mice reduced the incidence
of atherosclerosis in experimental models (Chang et al.,
1999; Horkko et al., 1999; Binder et al., 2003; Rose and
Afanasyeva, 2003).
In this article, we review recent new insights into
autoimmune-mediated mechanisms on development of
atherosclerosis, mostly based on our recent observations
and discuss the possible clinical signiﬁcance of circulating
oxLDL/b2GPI complexes and autoantibodies related to
these complexes.
CURRENT CONCEPTS ON ATHEROGENIC
MECHANISMS
Atherosclerosis is a pathological condition in which
arteries undergo thickening of the intima causing a
decrease in their elasticity. The aorta, coronary and
cerebral arteries are blood vessels most commonly
affected by atherosclerosis. The appearance of lipid laden
foam cells is a characteristic hystologic ﬁnding in early
atherosclerotic lesions. Figure 1A depicts a current
consensus of different events leading to the initial stages
of atherosclerosis. Hypercholesterolemia is commonly
associated with an elevation of LDL, which is the
lipoprotein that accumulates in foam cells. Increasing
LDL blood levels together with arterial shear stress may
produce a vascular inﬂammatory response, with the
adherence of circulating monocytes to endothelial cells
and the migration of these elements (LDL, oxLDL and
monocytes) into the intima. The oxidative modiﬁcation of
LDL may be further catalyzed by inﬂammatory cells at
FIGURE 1 Mechanisms of development of atherosclerosis. (A) General consensus of atherogenesis. (B) Possible mechanism of anti-b2GPI
autoantibody-mediated oxLDL uptake by macrophages in APS. (C) Proposed mechanism of development of thrombosis in APS.
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formation (oxLDL-loaded macrophages). Numerous pro-
inﬂammatory molecules and/or adhesion molecules also
participate in the development of atherosclerosis
(Cushing et al., 1990; Rajavashisth et al.,1 9 9 0 ;
Frostegard et al., 1993; Nakata et al., 1996). In addition,
macrophage scavenger receptors and various cell–cell
interactions, possibly via CD40 and CD40 ligands, have
been reported to be involved in the development of
atheroma (Mach et al., 1998). When the endothelial
surface of the atherosclerotic lesion becomes damaged
and unstable, it may rupture. This event is followed by
the activation of blood coagulation mechanisms such as
platelet aggregation and thrombi formation, which can
result in a complete occlusion of the blood vessel and
tissue or organ necrosis, as seen in acute myocardial and
cerebral infarction.
MACROPHAGES AND SCAVENGER RECEPTORS
Macrophages receptors for the speciﬁc uptake of LDL
were ﬁrst described by Goldstein et al. (1979) and
Yamamoto et al. (1984). These receptors are down-
regulated to prevent lipid overloading. Another type of
macrophage receptor was later described for chemi-
cally modiﬁed-LDLs and named scavenger receptors
(Goldstein et al., 1979; Brown and Goldstein, 1985).
These scavenger receptors are not down-regulated and
may lead to the accumulation of massive amounts of
intracellular lipids in macrophages, resulting in the
formation of macrophage-derived foam cells. Initially,
acetylated-LDL was used as a ligand to study scavenger
receptors, but this acetylation was not seen under
physiological conditions. In contrast, oxLDL was
described as a physiological ligand for scavenger
receptors and it was generated by peroxidation of LDL
when co-cultured with endothelial cells or when incubated
with a metal ion such as Cu
2þ or Fe
2þ.
Scavenger receptors (i.e. SR-A) were ﬁrst cloned by
Kodama and his colleagues (Kodama et al., 1988;
Kodama et al., 1990) and shown to be speciﬁc for both
acetylated-LDL and Cu
2þ-oxLDL. This was followed by
the description of several different types of scavenger
receptors, i.e. MARCO (a novel macrophage receptor
with collagenous structure), SR-B1, CD36, Macrosialin,
CD68, LOX-1, SREC, SRPSOX, etc. (Elomaa et al.,
1995; Rigotti et al., 1995; Ramprasad et al., 1995;
Sambrano and Steinberg, 1995; Sawamura et al., 1997;
Elomaa et al., 1998; Shimaoka et al., 2000; Minami
et al., 2001).
OXIDATIVE-MODIFICATION OF LDL
The LDL particle contains phospholipids, free chole-
sterols, cholesteryl esters, triglycerides and apolipoprotein
B (apoB). Both the lipids and apoB are subjected to
oxidation and apoB breaks down into fragments of
different sizes (from 14 to over 550kDa) by oxidative
attack, (Fong et al., 1987). A key feature of LDL’s
oxidation is the breakdown of the polyunsaturated fatty
acids to yield a broad array of smaller fragments including
aldehydes and ketones that can become conjugated to
amino lipids or to apoB (Esterbauer et al., 1987). The
polyunsaturated fatty acids in cholesterol esters, phospho-
lipids and triglycerides are subject to free radical-initiated
oxidation and can participate in chain reactions that
amplify the damage. Recently, two oxidized fatty acid
components have been described, 9- or 13-hydroxyocta-
decadienoic acid (9-and 13-HODE). These activate
peroxisome proliferator-activator receptor g (PPARg),
a transcriptional regulator of genes linked to lipid
metabolism that up-regulate the CD36 scavenger receptor
(Nagy et al., 1998). Thus, lipid components of oxLDL
g e n e r a t e db yP P A R g activation can promote foam
cell formation.
Linoleic acid is a predominant polyunsaturated fatty
acid in LDL present mainly as a cholesterol ester
(Weidtmann et al., 1995). In mild oxLDL, cholesteryl
hydroperoxyoctadecadienoic acid (Chol-HPODE) and
cholesteryl hydroxyoctadecadienoic acid (Chol-HODE)
are the main products of oxidation (Kritharides et al.,
1993). It has been reported that Cho-HPODE inactivate
platelet-derived growth factor (van Heek et al., 1998).
The oxidative breakdown of either free polyunsaturated
fatty acids or those esteriﬁed at the sn-2 position of
phospholipids result in fatty acid-hydroperoxides which
form highly reactive products containing aldehyde and
ketone functions. Such active functions can form Schiff
base adducts with lysine residues of the apoB moiety of
LDL or other proteins and with primary amine
containing phospholipids such as phosphatidylserine and
phosphatidylethanolamine.
Cholesterol is also converted to oxysterols and it is
especially oxidized at the 7-position. 7-Hydroxychole-
sterol (both free and esteriﬁed) is the major oxysterol
formed during early events in LDL oxidation, with
7-ketocholesterol dominating at later stages (Brown et al.,
1997). Recent studies indicated that elevated plasma level
of 7b-hydroxycholesterol is associated with an increased
risk of atherosclerosis (Brown and Jessup, 1999). At a
later stage of LDL oxidation, cholesterol or 7-keto-
cholesteryl esters of 9-oxononanoate derived from
cholesteryl linoleate, are detected as the most abundant
fraction of oxidized cholesteryl linoleate (Kamido et al.,
1992; Kamido et al., 1995; Hoppe et al., 1997). As a result
of oxidation, a large number of oxidative structures are
literally generated.
Chemically modiﬁed LDLs, such as MDA-modiﬁed
LDL, acetylated LDL and Cu
2þ-mediated oxLDL, were
extensively examined as experimental models of
denatured LDL to study atherogenic mechanisms.
Among these models, trace amounts of Cu
2þ can induce
LDL oxidation, resulting in highly reproducible LDL
damage (Kleinveld et al., 1992). This process leads to an
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with the LDL oxidized by cells or to oxLDL extracted
from arterial atherosclerotic plaques. Incubation of LDL
with several different types of cells, or with Cu
2þ even
in the absence of cells, results in an oxLDL structure
with similar properties (Parthasarathy et al., 1990).
There is general consensus that Cu
2þ-oxLDL is a
relevant autoantigen because the oxLDL found in
atheromatous lesions and the oxLDL extracted from
atherosclerotic lesions, exhibited similar physicochem-
ical and immunological properties to the Cu
2þ-oxLDL
(Yla-Herttuala et al., 1989). Thus, Cu
2þ-mediated
oxLDL seems to be a more suitable model for
physiological LDL rather than other chemically modiﬁed
LDL, such as MDA-LDL. In vivo, LDL might be
alternatively oxidized by released Cu
2þ from cerulo-
plasmin, the major copper-containing component of
mammalian plasma (Ehrenwald et al., 1994; Lamb and
Leake, 1994).
A POTENTIAL METABOLIC FORM OF OXLDL
(OXLDL/b2GPI COMPLEXES)
b2GPI is a 50kDa single-chain polypeptide composed
of 326 amino acid residues, arranged in 5 homologous
repeats known as complement control protein domains.
b2GPI’s ﬁfth domain contains a patch of positively
charged amino acids that likely represents the binding
region for phospholipids (Bouma et al., 1999; Hoshino
et al., 2000). b2GPI binds strongly to negatively
charged molecules, such as phospholipids, heparin and
certain lipoproteins as well as to activated platelets
and apoptotic cell membranes. This binding may aid
the clearance of apototic cells from circulation (Inanc
et al., 1997).
Antiphospholipid antibodies such as aCL and LA, have
been found in patients with SLE in association with
venous and arterial thromboembolic manifestations, with
pregnancy morbidity (Harris et al., 1983; Hughes et al.,
1986). Subgroups of SLE patients with these clinical and
serologic features were classiﬁed as having APS. It is now
widely agreed that some phospholipid-binding plasma
proteins are the relevant antigens for antiphospholipid
antibodies. In 1990, two groups of investigators (McNeil
et al., 1990; Matsuura et al., 1990) independently reported
that autoimmune aCL antibodies were directed to
cardiolipin/plasma cofactor (b2-GPI) complexes. We
further reported that aCL recognize a neo-epitope on
b2-GPI when adsorbed onto hydrophobic surfaces with a
negative charge such as an oxygenated polystyrene plate
(Matsuura et al., 1994).
We recently demonstrated (Hasunuma et al., 1997;
Kobayashi et al., 2001; Liu et al., 2002; Kobayashi et al.,
2003) the speciﬁc interaction between Cu
2þ-oxLDL and
b2GPI by ELISA (b2GPI by ELISA and optical sensor)
andopticalbiosensor(Fig.2).Further,twooxLDL-derived
lipid ligands speciﬁc for b2GPI, namely, oxLig-1 and
oxLig-2, were identiﬁed as 7-ketocholesteryl-9-carbox-
ynonanoate [9-oxo-9-(7-ketocholest-5-en-3b-yloxy) non-
anoic acid (IUPAC)] and 7-ketocholesteryl-12-carboxy
(keto) dodecanoate, respectively (Fig. 3). Cholesteryl
linoleatepresentinLDLisamajorcorelipidandrepresents
the candidate for a precursor of these ligands.
The initial in vitro interaction of Cu
2þ-oxLDL with
b2GPI is due to electrostatic interactions between v-
carboxyl functions and lysine residues of b2GPI and is
reversible by Mg
2þ treatment. The interaction later
progresses to a much more stable bond such as Schiff
base formation with v-aldehydes (Fig. 4). Interestingly,
the negative charges of oxLDL generated by incubating
with Cu
2þ were neutralized by the interaction with b2GPI
(Fig. 5). As described later, we demonstrated the presence
of stable oxLDL/b2GPI complexes in sera of patients with
various chronic diseases, such as APS, SLE, chronic renal
diseases and diabetes mellitus, as well. These complexes
are occasionally present in APS and SLE patients as
immune complexes with IgG anti-b2GPI antibodies
(Kobayashi et al., 2003). The strength of the bond formed
and the neutralization of the charges by the complexes
may contribute to their long-term presence in the
blood stream.
FIGURE 2 Molecular interactions among LDLs, b2GPI, and anti-b2GPI autoantibodies detected by optical biosensor (IAsys). (A) Native LDL or
oxLDL binding to solid phase b2GPI. (B) Native LDL or oxLDL binding to solid phase WB-CAL-1 antibody (anti-b2GPI autoantibody) in the presence
of b2GPI.
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PHAGOCYTOSIS OF OXLDL/b2GPI COMPLEXES
We ﬁrst demonstrated in 1997 that the invitro macrophage
uptake of
125I-Cu
2þ-oxLDL was signiﬁcantly enhanced in
the presence of b2GPI and IgG anti-b2GPI autoantibodies
(Hasunuma et al., 1997). Further, the macrophage uptake
of liposomes containing b2GPI ligands (oxLig-1 and
oxLig-2) was also enhanced conﬁrming the previous
results (Kobayashi et al., 2001; Liu et al.,2 0 0 2 ;
Kobayashi et al., 2003). These ﬁndings indicate that
IgG anti-b2GPI autoantibodies may be atherogenic.
The in vivo oxLDL uptake is likely mediated by Fcg
receptors rather than by scavenger receptors (Fig. 1B).
In contrast, most recent reports indicated that natural
antibodies (mainly of the IgM class) derived from
hyperlipidemic mice reduced the incidence of athero-
sclerosis in experimental models (Chang et al., 1999;
Horkko et al., 1999; Binder et al., 2003; Rose and
Afanasyeva, 2003). Because, Fcm receptors have poor
phagocytic properties, possibly making IgM class of
autoantibodies and/or natural antibodies anti-atherogenic
(or protective).
AUTOIMMUNITYAND ATHEROSCLEROSIS
Antiphospholipid antibodies, i.e. b2GPI-dependent aCL,
anti-b2GPI and anti-prothrombin antibodies have been
associated with several forms of cardiovascular diseases
FIGURE 4 Mechanism of complex formation between oxLDL and b2GPI.
FIGURE 3 Structures of oxLDL derived ligands, speciﬁc for b2GPI. (A) Cholesteryl linoleate (as a precursor), (B) and (C) Major ligands for b2GPI
(oxLig-1 and oxLig-2, respectively), (C) A common structure of the b2GPI ligands. oxLig-1:
1H-NMR (300.1MHz, CDCl3):d ¼ 5:71 (s, 1 H, H-6),
4.78-4.69 (m, 1 H, H-3);
13C-NMR (75.5MHz, CDCl3): d ¼ 202:5; 179.7, 173.4, 164.5, 127.1, 72.4, 55.2, 50.4, 50.2, 45.8, 43.5, 39.9, 38.7, 36.6, 36.1,
29.2, 28.9, 28.4, 25.3, 25.0, 24.2, 23.2, 23.0, 19.3, 17.7, 12.4; m/z (FD-MS): 571 [(M þ H)
þ,C 36H59O5 requires 571].
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(Vaarala, 1998; Brey et al., 2001). The ﬁnding that some
aCL from patients with APS were capable of cross-
reacting with oxLDL (Vaarala et al., 1993), suggested that
antiphospholipid antibodies might promote atherosclero-
sis. The plasma protein b2GPI, now regarded as the
relevant antigenic target for antiphospholipid antibodies,
has been found in atherosclerotic lesions together with
immunoreactive CD4 lymphocytes (George et al., 1999).
These observations not only support the hypothesis of an
autoimmune mechanism in atherosclerosis but also may
indicate a role for antiphospholipid antibodies in this
process. It is possible that systemic autoimmune diseases
may cause vascular inﬂammation resulting in oxidation of
LDL and these changes along with a series of biochemical
events and complex molecular interactions may produce
an autoantibody response leading to atherosclerosis.
The premature (or accelerated) development of athero-
sclerosis has been recently recognized in patients with
systemic autoimmune diseases (Ward, 1999; Aranow and
Ginzler, 2000; Van Doornum et al., 2002). The traditional
risk factors for atherosclerosis as well as autoimmune
disease treatments (i.e. steroids) failed to account for these
changes (Esdaile et al., 2001). Today’s SLE survival rate
(.80% over a 10-year follow-up) may have uncovered
hidden causes of mortality and morbidity. Systemic lupus
erythematosus mortality rates due to cardiovascular
disease have surpassed that from SLE disease itself or
from complications such as infections in most studies
(Schattner and Liang, 2003). In addition, abnormal
myocardial perfusion results by Tc99m emission tomogra-
phyhavebeenreportedinabout43%ofasymptomaticSLE
patients and increased carotid intima medial thickness
(IMT) with atherosclerotic plaques have also been
demonstrated by B-mode ultrasound in over 33% of these
patients. Autoantibodies against oxLDL, phospholipids
and Lp(a), have been proposed as alternative mechanisms
as well as certain biochemical and genetic abnormalities
(Lockshin et al., 2001). Although venous thromboembolic
complicationsarethemostcommonclinicalﬁndinginAPS
patients(Harrisetal.,1986;Ginsburgetal.,1992;Bickand
Baker,1999),about25%oftheAPSpatientsenrolledintoa
European cohort of 1,000 patients presented an arterial
thrombotic event (myocardial infarction, cerebrovascular
accident, angina, etc.) as the initial clinical manifestation.
Whenallthearterialthromboticeventswereconsidered,up
to 31% of the patients presented these complications
(Cervera et al., 2002).
ANTIPHOSPHOLIPID SYNDROME
AND ATHEROSCLEROSIS
Elevated serum levels of antiphospholipid antibodies
along with thrombotic events of both the venous and
arterial vasculature, or with pregnancy morbidity rep-
resent the major features of APS. APS may be present in
the context of a systemic autoimmune disorder i.e. SLE
(Hughes et al., 1986). Antiphospholipid antibodies appear
to increase the risk of thrombosis by at least two-fold in
the context of an autoimmune disease (Wahl et al., 1997).
In APS, recurrence rates of up to 30% for thrombosis with
a mortality of up to 10% over a 10-year follow-up period
have been reported (Shah et al., 1998). Antiphospholipid
syndrome is the most common cause of acquired
hypercoagulability in the general population.
Antiphospholipid antibodies are a heterogeneous group
of autoantibodies. These antibodies are characterized by
their reactivity to negatively charged phospholipids,
phospholipid/protein complexes and certain proteins
presented on suitable surfaces (i.e. activated cell
membranes, oxygenated polystyrene) (Matsuura et al.,
1994; Roubey, 1994). Several plasma proteins that
participate in coagulation and interact with phospholipids
have been described as antiphospholipid cofactors, i.e.
b2GPI, prothrombin and annexin V. b2GPI has been
shown to be a relevant antigenic target for antiphospho-
lipid antibodies (McNeil et al., 1990; Matsuura et al.,
1990; Matsuura et al., 1992; Matsuura et al., 1994).
Binding of antiphospholipid antibodies to b2GPI may
interfere with the anticoagulant functions promoting
thrombosis. Anti-b2GPI antibodies have been reported
as more speciﬁc for thrombosis and APS than aCL
antibodies (Tsutsumi et al., 1996) and recent prospective
studies have shown that aCL antibodies, particularly
b2GPI-dependent, or anti-b2GPI antibodies are important
predictors for arterial thrombosis (myocardial infarction
and stroke) in men (Vaarala, 1998; Brey et al., 2001;
Lopez et al., 2004). These studies suggest that b2GPI and
anti-b2GPI antibodies play a pathogenic role in the
development of thrombosis, particularly in arterial
thrombosis (atherosclerosis) in SLE and APS patients.
We have demonstrated that oxLDL, not native LDL,
binds b2GPI, initially forming dissociable electrostatic
complexes followed by more stable complexes bound by
covalent interactions (Kobayashi et al., 2003). In addition,
FIGURE 5 Agarose electrophoresis of oxLDL/b2GPI complexes.
oxLDL12h: LDL was oxidized by incubating with Cu2þion for 12h.
Oxidized LDL12h-b2-GPI16h: complexes prepared by incubating
oxLDL12 and b2GPI for 16h at 37 8C.
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occurrence in both APS and SLE patients without APS
and have demonstrated stable oxLDL/b2GPI complexes
in more than 60% of these patients. However, serum levels
of these complexes were not associated with the activity of
SLE or with any major clinical manifestation of APS
(Lopez et al., 2004). Although it can be hypothesized that
this interaction might be related to chronic inﬂammation
of the vasculature that occurs in autoimmune patients, the
mechanism(s) for the increased oxidation of LDL are not
fully understood. Signiﬁcantly high serum levels of
oxLDL/b2GPI complexes ﬂuctuated widely at different
time intervals over a 12-month follow-up from 6 SLE
patients. This suggests that oxidation and formation of
complexes are very active processes under unknown
regulatory mechanism(s). Stable oxLDL/b2GPI com-
plexes may be clinically relevant as they have been
implicated as atherogenic autoantigens and their presence
may represent a risk factor or an indirect but signiﬁcant
contributor for thrombosis and atherosclerosis in
patients with an autoimmune background (Kobayashi
et al., 2003).
WehavealsomeasuredserumlevelsofIgGanti-oxLig-1
(oxLDL)/b2GPI autoantibodies in patients with APS and
evaluated their association with the major clinical
manifestations of APS (Kobayashi et al., 2003; Lopez
et al., 2003). IgG autoantibodies against oxLig-1/b2GPI
were signiﬁcantly elevated in about 40% of patients with
APS as compared to SLE patients without APS. Further,
theseantibodiesshowedastrongercorrelationwitharterial
thrombosis than venous thrombosis and pregnancy
morbidity. Anti-oxLig-1/b2GPI antibodies were present
in 3 of 4 SLE patients with active disease followed over a
12-monthperiod,while2patientswithinactivediseaseand
oxLDL/b2GPI complexes did not have these antibodies
(Lopez et al., 2004). The coexistence of oxLig-1/b2GPI
autoantibodies with oxLDL/b2GPI complexes, suggest
that these two elements interact perhaps forming circulat-
ing immune complexes (oxLDL/b2GPI/antibody). Actu-
ally, we detected such immune complexes in serum
samples of SLE and/or APS in the most recent study
(Kobayashi et al., 2003). This observation along with the
increased macrophage uptake of oxLDL/b2GPI com-
plexes in the presence of anti-oxLig-1/b2GPI antibodies
(Hasunuma et al.,1997; Tinahones etal.,1998; Kobayashi
et al., 2001; Liu et al., 2002), provide a possible explana-
tion for the accelerated development of atherosclerosis in
autoimmune patients.
CONCLUSION
Current atherosclerosis research at different levels i.e.
histopathological, biochemical and immunological con-
tinues to unravel the complex nature of this process. New
factors are being investigated and unique interactions
among diverse factors described, all resulting in a better
understanding of atherogenic mechanism(s). In addition to
the oxidative modiﬁcation of LDL, the action of local
solublemediatorsofinﬂammationandchemotactic factors
and the accumulation of immune cells (macrophages and
T lymphocytes) in response to various external and/or
internal stimuli, an active humoral immune response has
been recently incorporated into the process. A signiﬁcant
role of antiphospholipid antibodies in the development of
atherosclerosis was proposed when some groups reported
inSLE patientsthe presence of antibodies tooxLDL,some
with cross-reactivity with aCL antibodies, as well as the
localization of b2GPI in the human atherosclerotic
plaques. The interaction between oxLDL and b2GPI to
form circulating complexes strongly suggests that this
complex is an atheroantigen. This interaction has been
further characterized and the oxLDL-derived ligand
(oxLig-1) speciﬁc for b2GPI has been identiﬁed and
synthesized. Antiphospholipid syndrome patients may
produce antibodies to this complex and the resulting
circulating immune complexes trigger atherosclerotic
changes. The physiologic relevance of this ﬁnding has
been demonstrated in vitro by the enhanced macrophage
uptake of oxLDL/b2GPI/antibody complexes. The anti-
bodies used in these experiments were aCL antibodies
b2GPI-dependent or anti-b2GPI antibodies. The possible
participation of Fcgreceptorsinthe increased macrophage
uptake of oxLDL-containing complexes seems to be
particularlyimportantinthedevelopmentoffoamcellsand
atherosclerotic plaques in the intima of arteries.
Stable and possibly pathogenic oxLDL/b2GPI com-
plexes were demonstrated in the serum of both SLE and
APS patients, but anti-oxLDL/b2GPI (oxLig-1) anti-
bodies seem to be restricted to SLE patients with APS or
primary APS. Further, the association of these antibodies
with arterial thrombosis was stronger than with venous
thrombosis in these patients. At this point, these results
should be interpreted in the context of an autoimmune
disease. We have also detected oxLDL/b2GPI complexes
in patients with syphilis but not in rheumatoid arthritis,
indicating that oxidation of LDL and the formation of
complexeswithb2GPIisnotrestricted toSLE. Incontrast,
both patient groups, syphilis and rheumatoid arthritis, did
not develop anti-oxLDL/b2GPI (oxLig-1) antibodies.
These antibodies seem to be restricted to SLE and APS
and we hypothesize that the presence of these antibodies
accelerates the development of atherosclerosis (Grainger
and Bethell, 2002).
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